Somatic RET mutations have been identi®ed in a variable proportion (about 30 ± 70%) of sporadic Medullary Thyroid Carcinoma (MTC) cases. They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of ®ve critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A). An in vitro transforming activity has already been demonstrated for these mutations. A few dierent MTC somatic mutations have been reported so far whose biological activity has still to be tested. In this paper we report the identi®cation, in two MTC tumor samples, of two interstitial deletions of 48 bp and 6 bp occurred in exons 10 and 11 respectively. Both were somatic heterozygous in frame mutations, not involving any cysteine residue. Moreover, the expression of a full length RET cDNA carrying one of the two deletions demonstrated a strong transforming capacity in NIH3T3 cells.
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Keywords: RET proto-oncogene; MTC patients; somatic mutations; in frame deletions; transformation assay Mutations of the RET proto-oncogene are associated with dierent genetic disorders depending on whether they induce loss of function, as in the case of Hirschsprung disease (HSCR), or gain of function, as in the case of Multiple Endocrine Neoplasia type 2 (MEN2A and MEN2B) and Familial Medullary Thyroid Carcinoma (FMTC) (see Pasini et al., 1996 for a review). The ability of most missense mutations detected in the latter inherited cancer syndromes (and related sporadic tumors) to activate RET into a dominant transforming oncogene has been demonstrated in vitro (Asai et al., 1995; Borrello et al., 1995; Santoro et al., 1995; Songyang et al., 1995) . For example, the Met918Thr substitution (exon 16), typical of the MEN2B phenotype and frequently identi®ed as somatic mutation in sporadic MTCs Mulligan and Ponder, 1995) , has been shown to change the substrate speci®city of the RET tyrosine kinase domain and to increase its enzymatic activity Santoro et al., 1995; Songyang et al., 1995) . Similarly, missense mutations involving any of the cysteine residues 609, 611, 618 and 620 in exon 10 or cysteine 634 in exon 11, typical of the MEN2A and FMTC phenotypes and rarely identi®ed in sporadic MTCs Mulligan et al., 1994; Romei et al., 1996) , have been demonstrated to promote a ligand independent RET dimerization leading to its constitutive enzymatic activation (Asai et al., 1995; Borrello et al., 1995; Santoro et al., 1995) . On the contrary, the biological eect of other RET mutations identi®ed in a few FMTC families (Glu768Asp in exon 13 and Leu804Val in exon 14) or in sporadic MTC cases (Ala883Phe in exon 15 and an in frame D6 bp removing cys630 and Asp631 in exon 11) Bolino et al., 1995; Eng et al., 1995) , has not been reported.
In the process of screening two large sets of Italian sporadic MTC cases (Romei et al., 1996; Gullo et al., in preparation) for possible causative RET mutations, two interstitial deletions aecting exon 10 and exon 11 have been observed in two dierent MTC patients.
The ®rst deletion was identi®ed in a 28-year-old female presenting with a 3 cm nodule in the right thyroid lobe, evident lymph node involvement in both sides of the neck, elevated serum calcitonin levels and no family history of thyroid tumors. The patient was treated in 1988 with thyroidectomy and bilateral node dissection. Hystology con®rmed the diagnosis of MTC with lymph node metastases (T3N1bMO). Serum calcitonin remained elevated, indicating that the surgical procedure was not curative and new clinically detectable node metastases appeared 10 months later. The patient was submitted to additional dissection of cervical lymph nodes in 1989, 1990, 1991 and 1994 . Molecular analysis of RET mutations was performed on two lymph nodes metastases collected at the second and fourth operation from the opposite side of the neck.
Unfortunately, the primary tumor was not available in this patient. At the present time the patient is still alive, but with persistent disease as demonstrated by elevated calcitonin levels with evidence of distant metastases. Using DNA from the two metastatic lymph nodes of this patient, PCR ampli®cation of RET exon 10 revealed, in both samples, the presence of a band shorter than that obtained with germline DNA, as shown in Figure 1 .
The abnormal PCR product, subcloned into the pCRII vector (TA cloning kit, InVitrogen) and sequenced using a sequenase kit and manufacturer's protocol (Amersham) (see Romeo et al., 1994 for details), showed a 48 bp interstitial deletion which spans nucleotides 1774 ± 1821 of the RET proto-oncogene (with numbering starting at the ATG codon). The deletion removes therefore 16 aminoacids (codons 592?607), does not introduce any new residue or involve any cysteine. The results were con®rmed by digesting, as previously described , the exon 10 PCR product with MaeIII, a restriction enzyme whose recognition site (/GTNAC) is created at the junction between the two breakpoints (TTGTTACCTG) (Figure 1) .
The second deletion was identi®ed in a 32-year-old male who noted a mass in his neck in June 1993. Physical examination revealed a nodule in the right thyroid lobe and bilateral neck adenopathies. A ®ne needle aspiration biopsy of the thyroid nodule led to the diagnosis of MTC, con®rmed by elevated levels of serum calcitonin and carcinoembryonic (CEA). No distant metastases (MO) were detected nor signs or symptoms of MEN2 syndrome were present in the patient and his family. A total thyroidectomy and bilateral radical neck dissection was performed in July 1993. Histopathologic evaluation disclosed a single 8 cm nodule of MTC occupying the whole right lobe and in®ltrating soft tissues of the neck, and bilateral nodal spread (pT4N1b). A post-operative clinicoinstrumental re-evaluation unveiled residual neck disease, which was treated surgically in January 1994. Despite this, the disease progressed with distant metastatic spread involving mediastinum, bones and liver. In January 1996 the patient was still alive but no further information is available. SSCP analysis of exon 11 of the RET proto-oncogene , ®rst performed on both a neck lymphonodal metastasis and the germline DNA of this patient, revealed a marked abnormal pattern only in the tumor DNA sample (data not shown). After cloning and sequencing as described above, the abnormal PCR product showed an in frame deletion of 6 bp (nucleotides 1894 ± 1899 of the RET cDNA) which removes a glutamic and a leucine residue (codons 632 and 633) adjacent to the cysteine 634. Since the deletion abolishes one of the ®ve AluI restriction sites of the RET exon 11, the absence of this deletion in the germline DNA was con®rmed by restriction analysis carried out as previously described (Figure 2, upper part) . The same protocol was used for excluding any ampli®cation error possibly occurred during the detection of the deletion, as reported in Figure 2 (bottom part). Subsequently, AluI restriction analysis of RET exon 11 revealed the presence of the D6 bp deletion also on both the primary tumor and a second chest lymphonodal metastasis (data not shown).
The potential presence, in tumor samples from both patients, of additional mutations which could possibly contribute to the disease phenotype (Marsh et al., 1996) , was investigated as reported (Romei et al., 1996) only in exons 10, 11 and 16 but no additional alterations were detected.
In order to demonstrate a biological eect of at least one of the two deletions, the in vitro transforming activity of the RET mutant carrying the D6 bp deletion was tested in a focus formation assay on NIH3T3 mouse ®broblast cells in comparison with the MEN2A (Cys634Arg) and the MEN2B (Met918Thr) RET mutated cDNAs . In particular, the 3.5 kb full-length cDNA of RET was cloned into the pAlter vector (Promega) and site-directed mutagenesis was performed using an in vitro oligonucleotide mutagenesis system (Promega) as already reported . Each mutant cDNA was entirely sequenced and then inserted into the NheI site of the eukaryotic expression vector pCep9b, carrying the neomycin resistance gene (a gift from B Nelkin). NIH3T3 cells, 2610 5 , were transfected by calciumphosphate co-precipitation using 100 ± 500 ng plasmid DNA and 25 mg mouse carrier DNA. Transformed foci were grown in 5% calf serum DMEM and either ®xed and counted or isolated for further studies 14 days after transfection. Two dierent NIH3T3 transfection assays demonstrated that the D6 bp deletion activates RET into a transforming oncogene with a 4.8 and a 30.8-fold increased activity with respect to the MEN2A-and MEN2B-RET constructs, respectively (Figure 3) .
The remarkably strong transforming activity shown by the D6 bp in frame deletion correlates very well with the clinical severity of the corresponding tumor, characterized by an unusual aggressive progression with multiple and recurring metastases. A similar rate of tumor growth was also present in the ®rst MTC patient, characterized by the D48 bp in frame deletion in two lymph nodes collected during two dierent surgical procedures. These observations suggest that the two deletions might have played a role in initiating the corresponding MTCs. However, recent data demonstrate a role of RET somatic mutations in Figure 1 (left) Poly acrylamide gel electrophoresis (PAGE) of the PCR products of exon 10 obtained, as already described Romei et al., 1996) , from both tumor (T) and constitutional (C) DNA of the patient carrying the D48 bp deletion and from a normal control (N) DNA. (right) PAGE of the PCR products of exon 10 obtained from the same DNA samples as described above, after cleavage with MaeIII restriction enzyme. The normal 187 bp band, present in all the three lanes, is not cleaved by the restriction enzyme while the deleted 139 bp band, which should be present in the tumor DNA of the patient (T), is no longer visible after MaeIII restriction and is replaced by a 99 bp band and a 40 bp band (not visible, being run out of the gel). No MaeIII restriction sites are normally present in the PCR product of exon 10
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In frame deletions of the RET proto-oncogene I Ceccherini et al tumor progression, rather than in the initiation step, in sporadic MTC patients . Since it is impossible to test the presence of the two deletions in microdissected subpopulations of the corresponding primary tumors, as suggested by Eng et al. (1996) , no conclusion can be drawn about the step at which the two mutations arose.
Contrary to HSCR where a wide variety of dierent mutations can cause a loss of function of the RET proto-oncogene leading to intestinal aganglionosis Seri et al., in press ), the peculiar clustering of most MEN2 and FMTC mutations has suggested the presence of a limited number of mechanisms through which missense mutations can activate RET into a dominant oncogene (Asai et al., 1995; Borrello et al., 1995; Santoro et al., 1995; Songyang et al., 1995; Mulligan and Ponder, 1995) . In particular, with respect to exon 10 and exon 11 activating mutations, the substitution of one of the ®ve crucial cysteines, normally paired by intramolecular disulphide bonds, has been shown to leave the unpaired cysteine available for intermolecular bonding with an adjacent RET molecule which eventually leads to a ligand-independent dimerization (Asai et al., 1995; Borrello et al., 1995; Santoro et al., 1995) . Interestingly, the two interstitial deletions described here, although occurring in the same region, do not involve any cysteine residue. Moreover, both deletions remove a stretch of amino acids located just up-stream one of the crucial cysteine residues and a strong oncogenic eect has been demonstrated for the shorter one. RET-wt 9.6 x 10 3 <1 x 10-2 <1 x 10 -6
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RET-∆6 RET-wt Figure 3 Growth of foci following transfection of NIH3T3 cells with four dierent constructs, corresponding to the wild type RET proto-oncogene and to its activated versions MEN2A (Cys634Arg), MEN2B (Met918Thr) and D6 bp (del Glu632-Leu633), is shown together with a table summarizing the main parameters of each transformation from which the transformed foci/G418-resistant colonies ratio is calculated Although the observations above are not suitable to disclose the mechanism of oncogenic activation caused by the two deletions, it seems reasonable to postulate a role in either the formation of intramolecular disulphide bonds between paired cysteines or the kinetics of dissociation of the novel discovered RET binding complex, which includes the cell surface binding protein GDNF Receptor a (GDNFRa) and the glial-cell-line-derived neurotrophic factor (GDNF) as ligand (see MassagueÂ , 1996 for a list of references). Moreover, our ®ndings indicate that the screening for RET mutations, performed using restriction enzymes whose recognition sites are abolished or created by missense mutations, can fail to detect small deletions like the D6 bp described in this paper. Finally, the focus formation assay in NIH3T3 cells is con®rmed as a useful preliminary analysis to provisionally discriminate between activating and silent mutations. As a further example of this capacity, two rare substitutions (Glu768Asp and Leu804Val) associated with FMTC did not show, in this model system, any transforming activity (Borrello et al., in preparation) , thus challenging the previous conclusion regarding their possible oncogenic role (Bolino et al., 1995) .
